DTC Ad "Educational Quality" Questioned By Health Affairs Article
Executive Summary
FDA should require direct-to-consumer advertisements for pharmaceuticals to mention alternative treatments "by name or at least by class," according to an article in the March/April issue of Health Affairs.
You may also be interested in...
Direct-To-Consumer Ad Response Kit Proposed By Insurers Group
The National Association of Health Underwriters wants to develop patient education materials to help balance the demand for brand-name drugs created by direct-to-consumer advertising.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials